Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR.
Abreu MT, et al. Among authors: price j.
J Clin Gastroenterol. 2006 Jan;40(1):55-63. doi: 10.1097/01.mcg.0000190762.80615.d4.
J Clin Gastroenterol. 2006.
PMID: 16340635